Explore

Rapid Read Rapid Read
PCOS Renamed to Reflect True Nature of the Condition

PCOS Renamed to Reflect True Nature of the Condition

Polycystic ovary syndrome (PCOS) has been officially renamed to polyendocrine metabolic ovarian syndrome (PMOS) after a 14-year process involving over 14,000 patients and health professionals. The new name aims to more accurately describe the condition, which involves a large number of 'arrested follicles' rather than pathological ovarian cysts. This change is expected to improve diagnosis and treatment, as well as aid in identifying related conditions. The renaming is part of broader scientific updates, including research on pollution's impact on mental health and the discovery of Neanderthals as early dentists.
Rapid Read Rapid Read
Teal Health's At-Home Cervical Cancer Test Gains FDA Approval, Expands Access for Women

Teal Health's At-Home Cervical Cancer Test Gains FDA Approval, Expands Access for Women

Teal Health has developed an at-home cervical cancer screening test, which has been approved by the U.S. Food and Drug Administration (FDA). This test allows women aged 25 to 65 across the United States to collect a vaginal sample at home and send it to a lab for analysis. The test has shown a 96% accuracy rate in identifying pre-cancer, comparable to traditional in-office tests. The approval and subsequent rollout of this test mark a significant advancement in women's health, providing a convenient and private option for cervical cancer screening. The initiative aligns with efforts to eliminate cervical cancer, which the World Health Organization (WHO) has identified as an eliminable disease due to advancements in diagnostics and vaccination.
Trendline Trendline
John Cena Reveals Struggle with Demodex Blepharitis, Highlights Importance of Eye Health

John Cena Reveals Struggle with Demodex Blepharitis, Highlights Importance of Eye Health

John Cena Reveals Struggle with Demodex Blepharitis, Highlights Importance of Eye Health
Trendline Trendline
Johnson Johnson Launches New Psoriasis Pill, Aiming for Major Market Impact

Johnson Johnson Launches New Psoriasis Pill, Aiming for Major Market Impact

Johnson Johnson Launches New Psoriasis Pill, Aiming for Major Market Impact
Rapid Read Rapid Read
Teal Health's At-Home Cervical Cancer Screening Gains FDA Approval, Expands Access

Teal Health's At-Home Cervical Cancer Screening Gains FDA Approval, Expands Access

Teal Health has developed an at-home cervical cancer screening test, known as the Teal Wand, which has been approved by the U.S. Food and Drug Administration (FDA). This test allows women aged 25 to 65 across the United States to collect vaginal samples at home, which are then mailed to a lab for analysis. The test has shown a 96% accuracy rate in identifying pre-cancer, comparable to traditional in-office tests. The approval and subsequent rollout of this test mark a significant advancement in women's health, providing a convenient and private option for cervical cancer screening. The initiative aligns with efforts to eliminate cervical cancer, a goal supported by improved diagnostics and vaccination schedules. Teal Health's test has been incorporated into guidelines by the American Cancer Society and the Health and Human Services, reflecting its acceptance and potential impact on increasing screening rates.
Trendline Trendline
Epic Expands EHR Market Share Amid Decline in Overall Sales

Epic Expands EHR Market Share Amid Decline in Overall Sales

Epic Expands EHR Market Share Amid Decline in Overall Sales
Rapid Read Rapid Read
Supreme Court Upholds Mail-Order Access to Abortion Pill Mifepristone

Supreme Court Upholds Mail-Order Access to Abortion Pill Mifepristone

The U.S. Supreme Court has upheld the availability of mifepristone, an abortion medication, to be dispensed by mail, following a legal challenge from Louisiana. The state argued that the FDA's rules allowing remote prescription of mifepristone interfered with its abortion ban. The Fifth Circuit had previously ruled in favor of Louisiana, effectively banning mail-order mifepristone nationwide. However, the Supreme Court, in a 7-2 decision, granted a temporary stay, allowing the medication to remain available by mail. The case, Louisiana v FDA, is expected to return to the court on an official appeal. The decision comes amid ongoing legal challenges following the Dobbs decision, which overturned Roe v Wade.
Trendline Trendline
Arna Pharma and Slate Run Pharmaceuticals Launch Joint Venture and First Product

Arna Pharma and Slate Run Pharmaceuticals Launch Joint Venture and First Product

Arna Pharma and Slate Run Pharmaceuticals Launch Joint Venture and First Product
Trendline Trendline
Medical Condition Renaming Reflects Evolving Scientific Understanding and Patient Perspectives

Medical Condition Renaming Reflects Evolving Scientific Understanding and Patient Perspectives

Medical Condition Renaming Reflects Evolving Scientific Understanding and Patient Perspectives
Trendline Trendline
PCOS Renamed to PMOS to Reflect Broader Health Implications

PCOS Renamed to PMOS to Reflect Broader Health Implications

PCOS Renamed to PMOS to Reflect Broader Health Implications
Rapid Read Rapid Read
Medical Community Renames PCOS to Reflect Broader Understanding of Condition

Medical Community Renames PCOS to Reflect Broader Understanding of Condition

The medical community has officially renamed Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). This change comes after 14 years of collaboration between researchers and patients, aiming to better reflect the condition's nature as a whole-body hormonal and metabolic disorder rather than one primarily defined by ovarian cysts. The renaming process highlights the evolving understanding of the condition and the importance of patient perspectives in medical nomenclature. Dr. Richard Barnett, a historian of medicine, notes that disease names often change as scientific knowledge and patient perspectives evolve. The decision to rename PCOS is part of a broader trend in medical history where disease names are updated to reduce stigma and improve accuracy, as seen with the renaming of monkeypox to mpox.
Rapid Read Rapid Read
PCOS Renamed to PMOS to Address Misconceptions and Improve Diagnosis

PCOS Renamed to PMOS to Address Misconceptions and Improve Diagnosis

Polycystic ovary syndrome (PCOS), a condition affecting women's fertility and diabetes risk, has been officially renamed to polyendocrine metabolic ovarian syndrome (PMOS). This change, announced by a global science consortium, aims to better reflect the condition's complex nature beyond just ovarian cysts. The renaming effort, led by Verity, Monash University, and the Androgen Excess and PCOS Society, seeks to address the widespread misunderstanding that PCOS is solely a reproductive disorder. PMOS affects approximately 170 million people worldwide, with up to 70% undiagnosed. The new name emphasizes the condition's endocrine and metabolic impacts, which include insulin resistance, type 2 diabetes, and psychological symptoms. The change is expected to improve diagnosis and treatment by highlighting the condition's broader health implications.